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Background: More and more evidences demonstrate the significance of Signal transducers and activators of
transcription 3(STAT3) in oncogenesis and tumor development. However, little systematic researches have been
reported on the correlation between STAT3 and thymic epithelial tumor (TET).
Methods: Expression of STAT3 protein in 80 thymic epithelial tumors was detected by immunohistochemistry (IHC).
The difference of STAT3 expression was compared by the χ2 test. Estimation of survival was calculated using the
Kaplan-Meier method, and the statistical differences were analyzed using the Log-rank test.
Results: Positive expression of STAT3 protein was significantly associated with Masaoka staging and WHO
histological classification (P < 0.05), but not with age, gender, or tumor size. The rate of postoperative recurrence/
metastasis was 33.33% in STAT3-positive tumors, compared with 4.55% in negative ones (P < 0.05). 5-year survival
was significantly lower in STAT3-positive subjects (61.11%) than in negative ones (97.73%) (P < 0.01); In patients in
Masaoka stage III or IV and WHO B3 or C, 5-year survival rate of subjects positive in STAT3 (35.00%, 35.00%) was
statistically lower than that of the negative ones (92.31%, 91.67%). Cox regression analysis revealed that positive
expression of STAT3 protein was an independent prognostic factor of thymic epithelial tumors (HR = 9.325,
P = 0.044).
Conclusion: Positive expression of STAT3 protein increases along with the rising malignant degree of thymic
epithelial tumors. It may be considered as an independent prognostic parameter with good prognostic value to
evaluate the possibility of recurrence/metastasis in patients with thymic epithelial tumor.
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As frequently seen in the anterior mediastinum of
adults, thymic epithelial tumor (TET) originates from
thymic epithelial cells and comprises series of tumors
different in pathology and biological behavior, including
thymoma and thymic carcinoma. Now, the identification
of benignancy and malignancy is still based on Masaoka
staging and WHO histological classification [1], while
the sensitivity of them is still unsatisfactory. The bio-
logical markers, therefore, are of great clinical import-
ance to discriminate the benignant and malignant
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reproduction in any medium, provided the orIn recent years, Janus protein tyrosine kinases/Signal
transducers and activators of transcription (JAKs/STATs)
has been paid more and more attention on its role in
cellular signal transduction. Its downstream key molecules
STAT3 is expressed abnormally and activated in multiple
tumor tissues [2]. More and more evidences demonstrate
the significance of STAT3 in oncogenesis and tumor devel-
opment. However, little systematic researches have been
reported on the correlation between TET and STAT3. In
this study, we detected the expression of STAT3 in TETs
through IHC, to explore its role in distinction between ma-
lignancy and benignancy and its correlation to prognosis.Methods
General data
The present study was approved by the ethics committee
of the University and was in compliance with the Helsinkihis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was obtained from the family members of the patients.
Clinical data of patients with TET admitted to Provincial
Hospital Affiliated to Shandong University from March
1999 to June 2009, who underwent surgical resection, were
reviewed, and 80 patients with complete data were enrolled
and evaluated in this retrospective study. Samples in this
study were chosen from tumor tissues embedded in wax
from Pathology Department, with another normal thymic
tissue embedded in as the control. The study group
contained 47 males and 33 females ranging in age from
19 to 70 years (mean = 46.5 y). No severe complications
occurred during peri-operative period in any of the sub-
jects. No patient underwent radiotherapy or chemotherapy
prior to surgery. Complete resection was accomplished
in 69 patients (86.3%) and palliative resection/biopsy
was made in 11 (13.8%). The tumors were staged based
on Masaoka’s clinical staging into stage I (n = 11), stage II
(n = 14), stage III (n = 29) and stage IV (n = 4), and classified
histologically according to WHO Histological Classification
of Thymic Tumor 2004 into type A (n = 5), AB (n = 16), B1
(n = 10), B2 (n = 17), B3 (n = 10) and C (n = 22).
Main reagents
Rabbit anti-human STAT3 polyclonal antibody and IHC
kit were purchased from Santa Cruz, U.S.A; DAB color
development kit was purchased from Dako; all other
reagents were products above analytic pure, except
where otherwise indicated.
Immunohistochemistry
Slices were routinely dewaxed and hydrated through
IHC SP. Antibodies were diluted 1:200 and underwentFigure 1 The expression of STAT3 in TET tissue (SP, ×400).thermal repair. All other procedures were carried out
strictly according to the instruction of IHC SP kit. The
appearance of tan granules in plasma was considered
as a positive staining of STAT protein, and the positive
expression was scaled according to the ratio of positive
cells. 10 high power fields (×400) were chosen randomly
with 100 cancer cell in each to calculate the percentage
of positive cells. A slice was determined to be negative
if 0-10% of cells were tanned, or positive if tanned cells
were more than 10%. All slices were determined by
two pathologists with blindness, and a mutual agree-
ment was arrived at through discussion made in case
of any discrepancy.
Follow up
The patients were followed up regularly, with records of
sites and time point of tumor recurrence or metastasis.
Patients who died from recurrence or metastasis were
included into the survival analysis. The follow-up ended
at the end of May 2010, with a median follow-up of
61.5 months (12-134 months). All patients were followed
up, with a follow-up rate of 100%, through outpatient
reexamination, telephone and letters.
Statistical analysis
All statistic analyses were performed with SPSS 17.0
statistical software. The χ2 test was used to evaluate
differences in STAT3 expression. Estimation of survival
was calculated using the Kaplan-Meier method, and the
statistical differences were analyzed using the Log-rank
test. Cox regression multiple analysis was performed to
determine the independent prognostic risk indicators.
P < 0.05 was recognized as statistical significance.
Table 1 The expression of STAT3 in TET tissue and









TET tissues 36 44 80 45.00%
Normal
tissues
1 19 20 5.00% 10.982 P = 0.001
Total 38 62 100
The difference of STAT3 expression in TET tissues and peritumoral normal
thymic tissues is significant (P < 0 .01).
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STAT3 expression in TET tissue and peritumoral normal
thymic tissue
The positive expression of STAT3 in TET tissue appeared
to be obvious tanned granules located in plasma
(see Figure 1). 36 out of 80 patients (45%) were found
positive in expression of STAT3 protein in TET tissue,
while only 1 out of 20 (5%) peritumoral tissues wasTable 2 Correlation of STAT3 protein expression to
clinical pathology of patients







<60 59 25 34 42.37%
≥60 21 9 12 42.86%
Gender 0.000 >0.05
Male 47 20 27 42.55%




A 5 0 5 0
AB 16 4 12 25.00%
B1 10 4 6 40.00%
B2 17 8 9 44.44%
B3 10 4 6 40.00%
C 22 16 6 72.73%
Masaoka 8.623 <0.05
stage 33 12 21 36.36%
Stage I 14 4 10 25.57%
Stage II 29 16 13 55.17%
Stage III 4 4 0 100%
Stage IV
Tumor size, d/cm 0.235 >0.05
≤5 cm 18 9 9 50.00%
>5 cm 62 27 35 43.55%
Statistics showed STAT3 correlated significantly to both WHO classification
(χ2 = 13.742, P < 0.05) and Masaoka staging (χ2 = 8.623, P < 0.05), but not to
age, gender and tumor mass.found positive. The difference was significant (p < 0.01)
(see Table 1).
STAT3 expression with clinicopathological characteristics
of patients
Types and stages of STAT3 protein expression (percentage,
ratio) were as follows: A (0/5, 0%); AB (4/16, 25%), B1
(4/10, 40%), B2 (8/17, 44.44%), B3 (4/10, 40.00%), C (16/22,
72.73%), stage I (12/33, 36.36%), stage II (4/14, 25.57%),
stage III (16/29, 55.17%), and stage IV (4/4, 100%). Statistics
showed STAT3 correlated significantly to both WHO
classification (χ2 = 13.742, P < 0.05) and Masaoka sta-
ging (χ2 = 8.623, P < 0.05), but not to age, gender and
tumor mass (Table 2).
STAT3 expression with postoperative recurrence/
metastasis
Recurrence/metastasis was found in 14 patients under
follow-up, including 9 local recurrences and 5 remote
metastases (including 2 patients with coincident local
recurrence and remote metastasis), and the ratio of re-
currence/metastasis was 17.50%. 12 recurrence/metastasis
(33.33%) was noticed in patients positive in STAT3 protein
expression, compared with 2 (4.55%) in those negative, with
a significant difference (p < 0.05) (see Table 3).
STAT3 expression with prognosis of TET patients
Based on follow-up of 80 patients, the Kaplan-Meier
survival curve suggested a 5-year survival rate of 81.25%
(65/80) in all patients (Table 2 and Figure 2). The 5-year
survival rate was 61.1% (22/36) in patients positive in
STAT3 protein expression, and 97.73% (43/44) in those
negative, with a statistical significance suggested by
Log-rank test (p < 0.01) (Figure 3).
Our study involved 32 patients in type B3 or C, including
20 positive in STAT3 protein expression and 12 negative.
The 5-year survival was 35.00% (7/20) in patients positive
and 91.67% (11/12) in those negative, with significant differ-
ence proved by Log-rank test (p < 0.01) (Figure 4).
33 patients with thymic tumor in stage III or IV were
included in our study, including 20 positive in STATS
expression and 13 negative. 5-year survival was 35.00%Table 3 Correlation between STAT3 protein expression












Total 14 66 80 11.366 <0.01
The ratio of recurrence and metastasis between Stat3 protein positive and
negative is significantly different (χ2 = 11.366, P < 0.01).
Figure 2 Kaplan-Meier overall survival curve of 80 TET patients.
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negative, with statistical difference demonstrated by
Log-rank test (p < 0.01) (Figure 5).
Multivariate analysis
Cox regression multiple analysis found the independ-
ent prognostic indicators including Masaoka stagingFigure 3 Kaplan-Meier survival curve of patients with STAT3 protein(HR = 3.949, P = 0.016), complete excision (HR = 6.578,
P = 0.015) and STAT3 protein expression (HR = 9.325,
P = 0.044) for TET patients (Table 4).
Discussion
Thymic epithelial tumor mainly includes thymoma and
thymic carcinoma, and quite a few thymomas have certainexpression positive or negative.
Figure 4 Kaplan-Meier survival curve of patients in WHO type B3 and C.
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practice to evaluate precisely the malignancy degree
and its prognosis.
Multiple oncogenes and tumor suppressor genes have
been found correlated to oncogenesis, development and
metastasis of thymic epithelial tumors (TET) [3]. STAT3,Figure 5 Kaplan-Meier survival curve of patients in Masaoka stage IIIone of transcription factors under recent vigorous
researches, is considered as an oncogene correlated
closely to proliferation, differentiation, cellular apoptosis,
immune escape, vascularization, invasion and metastasis
in multiple malignancies [4]. Its abnormal expression
can be found in many solid tumors and hematopoieticand IV.
Table 4 Results of Cox regression multiple analysis
B SE Wald P HR 95% CI for HR
Age −0.013 0.028 0.226 0.634 0.987 0.934~1.043
Gender 0.159 0.764 0.043 0.835 1.172 0.262~5.241
Mass size 0.014 0.281 0.003 0.960 1.014 0.585~1.760
STAT3 expression 2.233 1.110 4.043 0.044 9.325 1.058~82.207
Complete excision 1.884 0.773 5.936 0.015 6.578 1.445~29.939
WHO type 0.806 0.561 2.068 0.150 2.239 0.746~6.717
Masaoka stage 1.373 0.573 5.754 0.016 3.949 1.286~12.128
B: Regression coefficient; SE: Standard error; Wald: Wald value; P: P value;
HR: Hazard ratio; CI: Confidence interval.
Cox regression multiple analysis found the independent prognostic indicators
including Masaoka staging (HR = 3.949, P = 0.016), complete excision
(HR = 6.578, P = 0.015) and STAT3 protein expression (HR = 9.325, P = 0.044) for
TET patients.
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head and neck, skin cancer, brain malignant glioma,
prostate cancer, lung cancer and liver cancer [5-11].
However, few researches have reported on relationship
between STAT3 and thymic epithelial tumors.
We detected the positive expression of STAT3 protein
in 45.00% of 80 TETs, compared with 5.00% in 20
para-tumorous normal tissues with significant significance
(P < 0.01), implying the possible role of STAT3 protein in
oncogenesis and development of TET and its potential
value as a parameter in molecular biology in diagnosis of
TET. Statistics showed expression of STAT3 protein
correlated to both Masaoka staging (χ2 =13.742, P < 0.05)
and WHO histological classification (χ2 = 8.623, P < 0.05).
Our findings of the rising expression rate of STAT3
protein along with the increasing malignant degree of
TET suggests that over expression of STAT3 may improve
the proliferation and differentiation of thymic tumor
cells and inhibit their apoptosis, and the excessively
activated STAT3 may improve the oncogenesis and
tumor development. No correlation was found by
statistics between positive expression of STAT3 protein
and gender, age, or tumor size of the patient. Overall
5-year survival in our 80 TET subjects was 81.25%, and
patients’ positive in STAT3 protein had the signifi-
cantly lower 5-year survival (61.11%) than the negative
ones (97.73%). Follow up post surgery revealed a higher
recurrence/metastasis rate (33.33%) in STAT3-positive
patients than in the negative ones (4.55%), with statistical
significance (P < 0.05).
Now, prognostic evaluation is mainly based on
Masaoka staging and WHO classification in the clinical
practice. Clinically, TET staged in III or IV belongs to
the invasive TET, relatively poor in prognosis and low in
probability of radical excision. However, thymic tumor
in type A or AB generally have good prognosis even if
they develop to the advanced stage, implying the
discrepancy between prognosis and staging [12-14]. Inour patients staged in III and IV, the 5-year survival were
35.00% and 92.31% respectively in STAT3-positive
patients and the negative ones, with significant differ-
ence (P < 0.01). No death analysis was made for patients
staged in I or II, for their relatively good prognosis and
lower probability of death. Thymic tumor in type A based
on 2004 WHO classification is considered a benignant
tumor, but thymic cancers have been occasionally
reported in type A [15]. B3 thymic tumor is a well dif-
ferentiated thymic cancer, and type C is thymic cancer,
both of which are highly malignant thymic epithelial
tumor with poor prognosis [13,16]. In these two types
of TETs in this study, the 5-year survival was 35.00% in
STAT3-positive patients, in contrast to 91.67% in the
negative ones, with significant difference (P < 0.01). All
these findings revealed the significant difference in
prognosis between patients differing in STAT3 expression
level but having the same stage and same type based on
Masaoka staging or WHO classification. Therefore, detec-
tion of STAT3 expression level may have vital importance
to evaluate the prognosis of TET, especially precise for the
highly malignant thymic epithelial tumor. Positive STAT3
means a bad prognosis, while the negative one means a
good prognosis.
Despite the guiding significance of WHO classification
and Masaoka staging in evaluation of the prognosis of
thymic tumor, the definition of membrane infiltration
has been made meaningless by the complete or partial
absence of membrane in some of them. Moreover, no
statistical difference in survival curve between Masaoka
stage I and II, between WHO type A and B1, between
B2 and B3, and between B3 and C [17-19] implies that it
is still far from perfect of Masaoka staging and WHO
classification to evaluate the prognosis. Our results from
Cox multivariate regression supports STAT3 protein
expression to be an independent prognostic factor
for TET patients (HR = 9.325, P = 0.044), which helps
establish a precise prognosis for patients with same
staging and classification. Therefore STAT3 may be
considered as a useful compensation for Masaoka staging
and WHO classification.
We believe that it is necessary to carry out a further
investigation on STAT3 gene, which may improve the
precision of clinical diagnosis of thymic epithelial tumor,
provide genetic diagnostic proofs, help the physicians
make a precise forecast for their patients, provide new
targets in genetically targeted therapy for thymic epithelial
tumor patients, and have a great importance in genetic
therapy for malignant thymic epithelial tumors not respon-
sive to radiotherapy and/or chemotherapy.
Conclusion
In summary, STAT3 may be used as an independent
parameter to evaluate prognosis for patients with thymic
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value in forecasting recurrence/metastasis, STAT3 may
improve the diagnostic accuracy and provide better
approaches in clinical practice for thymic epithelial tumor.
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